Renaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

Renaissance Technologies LLC reduced its position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 57.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 142,300 shares of the company’s stock after selling 194,440 shares during the period. Renaissance Technologies LLC owned about 0.69% of Protara Therapeutics worth $751,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in TARA. Bailard Inc. bought a new stake in shares of Protara Therapeutics in the 4th quarter valued at $157,000. Commonwealth Equity Services LLC boosted its position in Protara Therapeutics by 90.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after acquiring an additional 17,572 shares during the last quarter. Geode Capital Management LLC grew its holdings in Protara Therapeutics by 21.0% during the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after acquiring an additional 29,514 shares during the period. ADAR1 Capital Management LLC bought a new position in shares of Protara Therapeutics in the 4th quarter worth about $648,000. Finally, Oppenheimer & Co. Inc. raised its position in shares of Protara Therapeutics by 12.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company’s stock worth $1,064,000 after acquiring an additional 22,301 shares in the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Stock Performance

Shares of Protara Therapeutics stock opened at $3.46 on Friday. The company has a 50-day simple moving average of $4.01 and a two-hundred day simple moving average of $4.02. The stock has a market capitalization of $127.21 million, a PE ratio of -1.23 and a beta of 1.60. Protara Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09. As a group, equities research analysts forecast that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TARA has been the subject of several recent research reports. Scotiabank began coverage on Protara Therapeutics in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $12.00 price objective for the company. Lifesci Capital initiated coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday. Finally, Cantor Fitzgerald began coverage on shares of Protara Therapeutics in a research report on Friday, March 14th. They set an “overweight” rating for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Protara Therapeutics presently has an average rating of “Buy” and a consensus price target of $20.40.

Insider Buying and Selling

In related news, insider Jacqueline Zummo sold 21,224 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now owns 98,861 shares of the company’s stock, valued at $447,840.33. This trade represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.50% of the stock is owned by corporate insiders.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.